Compare Mesoblast Limited (MESO) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs United Airlines Holdings Inc — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while United Airlines Holdings Inc trades at $108.53 (market cap $35.76B). The key difference: United Airlines Holdings Inc is far larger — about 19.8× Mesoblast Limited's market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and United Airlines Holdings Inc for 46 Days on average.
| MESO | UAL | |
|---|---|---|
Market Cap | $1.81B | $35.76B |
Volume | 240,620 | 5,327,551 |
Sector | Health | Industrials |
52-Week High | $20.96 | $136.11 |
52-Week Low | $13.19 | $85.21 |
Typical Hold Time | 14 Days | 46 Days |
Enterprise Value | $1.89B | $52.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
United Airlines (UAL) trades at $110.17, down 1.53% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 10.32 and consistent earnings beats, including Q2 2026 EPS of $1.99 versus $1.88 expected. Revenue growth has climbed from $45.0B in 2022 to $59.1B in 2025, with net income margin improving to 5.67%. Recent news highlights aggressive customer acquisition efforts targeting Delta's premium flyers.
The outlook is mixed: analyst consensus is strongly bullish with a $158.10 price target and no sell ratings, but technical indicators and rising fuel costs pose near-term risks. Earnings sustainability and market share gains from competitor targeting present upside, while debt levels and operational volatility remain challenges for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
